40
Renovare Therapeutics raises $1M in first offering under Reg D 506(b)
Company raise · Raising · BOULDER, CO · Form D filed 2026-10-02
Renovare Therapeutics, a Delaware biotech corporation incorporated in 2026, is raising up to $1M under Regulation D 506(b) exemption. The company has sold $100K to one investor as of September 14, 2026, and seeks $900K more.
Note: Company incorporated in 2026 and filed Form D in October 2026; first raise on EDGAR; no placement agent listed.
First raise on EDGARother
How this compares
- Among 416 fund launches filed from CO in the same window it is larger than 13%; the CO median is $40M.
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
People on the filing
| Elizabeth A Scott | Executive Officer, Director |
| Stephanie Bryant | Director |
| Karin Payne | Executive Officer |
Signed by Elizabeth A. Scott, Chief Executive Officer.
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.